Heidelberg

• Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy … Pending
  2025-523010-89-00 3 Pulmonary arterial hypertension
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of In … Pending
  2025-523087-20-00 5 Duchenne muscular dystrophy
• Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Pending
  2025-523389-26-00 5 Relapsed/refractory primary central nervous system lymphoma
• A randomized, double-blind, placebo-controlled study to assess the effects of high concentration capsaicin patch (Qutenza) on neuropathic sy … Pending
  2025-523597-17-00 4 Painful diabetic peripheral neuropathy
• Efgartigimod as a first line attack therapy in demyelinating diseases of the central nervous system Pending
  2025-523654-13-00 10 Demyelinating diseases
• Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH). Pending
  2025-523672-23-00 4 Metastatic Castrate Sensitive Prostate Cancer - mCSPC
• A clinical study to investigate the safety and tolerability of efimosfermin alfa injection in participants with known or suspected F2- or F3 … Pending
  2025-523674-16-00 5 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• A pivotal clinical study to investigate the safety and efficacy of efimosfermin alfa injection in participants with biopsyconfirmed F2- or F … Pending
  2025-523675-39-00 5 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending
  2025-523793-16-00 4 Homeostatic iron regulator gene-related hereditary hemochromatosis
• A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta … Pending
  2025-523869-22-00 5 advanced or metastatic extrapulmonary neuroendocrine carcinoma
• Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent) Pending
  2025-523990-40-00 5 Newly diagnosed Multiple Myeloma in patients eligible for stem cell tr
• A study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with … Pending
  2025-524285-18-00 4 Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion
• ALTERNATION Trial: A Clinical Trial Evaluating Everolimus-Based, Calcineurin Inhibitor-Free Immunosuppression One Year After Liver Transplan … Pending
  2025-524312-11-00 5 Patients after the first year following liver transplantation
• The RAPID-Elapse study: Can the drug bupropion improve fatigue symptoms in patients with long COVID? Pending
  2025-524443-12-00 4 Post Covid Syndrome (PCS)
• Real-world study to evaluate how effective and safe Pegcetacoplan is in patients with rare kidney diseases called C3G or IC-MPGN in multiple … Pending
  2025-524487-37-00 6 Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MP
• Epcoritamab in Relapsed/Refractory Marginalzone Lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (EPOS-1) Pending
  2025-524879-23-00 4 Marginal Zone Lymphoma
• A multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority trial to investigate shortening treatment duration in … Pending
  2026-525640-14-00 6 Candidemia
• A study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with IV Bevacizumab Compared to Standard of Care IV Bevacizumab i … Recruiting
  2025-521712-19-00 5 2026-07-06 Colorectal Cancer
• Double-T - Improving outcomes in high-risk 2nd line relapsed/refractory Large B-Cell Lymphoma patients eligible for CAR-T-cell therapy with … Recruiting
  2025-523806-34-00 4 2026-07-06 relapsed/refractory Large B-Cell Lymphoma
• DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t … Recruiting
  2025-520565-51-00 5 2026-06-23 small cell lung cancer
• Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE) Recruiting
  2024-516896-34-00 9 2026-06-17 progressive/relapsed/refractory pediatric low-grade glioma (pLGG)
• A clinical trial of V940 with or without MK-3475A in people with non-small cell lung cancer (V940-014) Recruiting
  2025-522643-18-00 5 2026-06-16 Stage I NSCLC
• A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally … Recruiting
  2025-523524-53-00 9 2026-06-12 ADVANCED OR METASTATIC RENAL CELL CARCINOMA
• Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors Recruiting
  2025-523947-36-00 4 2026-06-10 Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherap

Showing 25–48 of 735 trials